
Bromantane (brand name Ladasten) is a synthetic stimulant and anxiolytic (anti-anxiety) compound.(1)(2) It is also written bromantan(3) or bromontan(4) and misspelled bromantine, bromontane, bromanatane, bromatine, bromatane, bromotane, bromantano or bromante.
Its main placebo-controlled human evidence is a 180-patient multicenter study in neurasthenia and somatogenic (physical-illness-related) asthenia, in which 100 to 150 mg per day for 28 days left 57.8% of ladasten patients in each diagnosis group rated “normal, not ill” on the CGI-S, a clinician-rated illness severity scale, a difference from the control groups reported as significant (p<0.05).(5) Its largest human dataset is a 28-day multicenter study of 728 patients with psychoautonomic syndrome and asthenic disorders (persistent fatigue and weakness) given 50 to 100 mg per day, in which 76.0% were responders on the CGI-S; no control group is reported.(6)
Two smaller placebo-controlled reports, by Avedisova and by Neznamov, come from institutions that the 180-patient paper lists as participating centres, so their results probably overlap with it. A 10-person healthy-volunteer study compared a single oral dose with placebo on EEG (a recording of brain electrical activity).(3) The dopamine, serotonin and gene-expression findings come from rats and rat tissue, so effects on focus, memory or motivation in healthy adults are inferred rather than measured.
Table of Contents
What is Bromantane?
Bromantane, with the formula C16H20BrN and PubChem CID 4660557, is a derivative of adamantane (a cage-shaped hydrocarbon ring).(7) It is a small synthetic molecule, not a peptide. Ladasten is its commercial name in Russia, where bromantane is grouped with the adamantane derivatives among the actoprotectors, defined as synthetic adaptogens (substances said to raise resistance to physical and mental strain) with a significant capacity to improve physical performance.(1) A pilot clinical trial describes ladasten as a combination of stimulant and anxiolytic effects that is unusual for psychostimulants.(2)
Production continued in Russia after 1991, mainly for sports medicine.(1) Other synthetic nootropics are grouped in the types of nootropics guide.
Bromantane at a glance: human evidence
| Study | Participants | Dose | Duration | Result |
|---|---|---|---|---|
| Voznesenskaia 2010, multicenter, single group | 795 patients enrolled, 728 analysed (91.6%), with psychoautonomic syndrome and asthenic disorders; 6 (0.8%) left because of adverse events(6) | 50 mg per day at the start, raised by the physician to up to 100 mg per day(6) | 28 days, plus assessment one month after | 76.0% responders on the CGI-S and 90.8% on the CGI-I (a clinician-rated improvement scale).(6) |
| Smulevich 2009, multicenter placebo-controlled, 4 parallel groups (randomization and blinding not described in the paper; 5 centres listed) | 180 patients with neurasthenia or somatogenic asthenia, 45 per group, 90 on ladasten(8) | 100 mg per day at the start, 100 to 150 mg per day(8) | 28 days, then 7 days of placebo | 57.8% of ladasten patients in each diagnosis rated “normal, not ill” on the CGI-S at the final visit, a difference from the control groups reported as significant (p<0.05); mild adverse events in 16 of the 90 ladasten patients (17.8%); no signs of withdrawal syndrome.(5) |
| Avedisova 2009, randomized single-blind, placebo (one centre of the multicenter study; results probably overlap) | 40 patients: 20 with neurasthenia and 20 with somatogenic asthenia, 10 per group in each diagnosis | Not stated in this report; the multicenter protocol used 100 to 150 mg per day | 28 days of ladasten or placebo | In neurasthenia, all 10 ladasten patients were rated “normal state, not ill” on the CGI-S at day 28 (95% confidence interval for the difference from placebo, 36 to 100%), while the placebo group showed no statistically reliable improvement; no adverse events in this group, and one patient had brief mild dizziness after stopping.(9) |
| Neznamov 2009, randomized blind, placebo (the Zakusov institute is a listed centre of the multicenter study; results probably overlap) | Patients with neurasthenia; n not stated in the abstract (full text could not be obtained) | Not stated in the abstract | 28 days of ladasten or placebo, then 1 week of placebo | Superior to placebo in the rate and degree of reduction of main asthenic symptoms; no withdrawal syndrome after stopping.(10) |
| Bogdan 2009 | Healthy volunteers; n not stated | Single 100 mg dose | Single dose | Improved psychophysiological parameters in mental fatigue; no behavioral toxicity.(11) |
| Viatleva 2000 | 10 healthy volunteers | Single oral dose, amount not stated | Single dose | EEG changes versus placebo; no change in subjective state or operator performance in untired men.(3) |
| Siuniakov 2006, pilot trial | n not stated | Not stated | Single administration | Psychostimulant action predominated over the anxiolytic action.(2) |
Limits: the multicenter patient study treated patients for 28 days and followed them for one month afterwards, so safety beyond that period has not been studied,(6) and the 728-patient study reports no control group, so its response rates cannot be separated from a placebo response.
Bromantane Dosage
The placebo-controlled multicenter study used 100 to 150 mg per day for 28 days.(8) The 728-patient study used 50 to 100 mg per day for 28 days,(6) and one healthy-volunteer study used a single 100 mg dose.(11) The Avedisova and Neznamov reports state no dose of their own. Use the Bromantane dosage calculator to convert a dose to body weight.
The Russian prescribing information for Ladasten gives single doses of 50 to 100 mg and a daily dose of 100 to 200 mg in two doses, not after 4 p.m., as a course of 2 to 4 weeks.(12) The label describes tablets taken by mouth regardless of meals.(12)
| Dose | Species and route | Source type | Result or note |
|---|---|---|---|
| 100 to 150 mg per day (start 100 mg) for 28 days | Human patients, route not stated | Study dose | Placebo-controlled multicenter study in neurasthenia and somatogenic asthenia.(8) |
| 50 to 100 mg per day for 28 days | Human patients, route not stated | Study dose | Multicenter study in asthenic disorders.(6) |
| 100 mg, single dose | Human healthy volunteers, route not stated | Study dose | Psychophysiological parameters in mental fatigue.(11) |
| Single dose 50 to 100 mg; 100 to 200 mg per day in two doses; not after 4 p.m.; 2 to 4 weeks | Human, oral tablets | Russian label dose | Regimen in the Ladasten prescribing information.(12) |
| 50 to 100 mg per day, often 50 mg; some report up to 150 mg per day | Humans, route not stated | Community anecdotal range | User reports, not a study dose; reports differ. |
| 30 mg/kg, single dose, equal to 4.86 mg/kg human equivalent, about 340 mg for 70 kg | Rat, route not stated | Animal dose, estimated equivalent, not a tested dose | Stimulated behavioral activity.(13) |
| 50 mg/kg, equal to 8.11 mg/kg human equivalent, about 568 mg for 70 kg | Rat, oral in one study and intraperitoneal (injected into the abdominal cavity) in another | Animal dose, estimated equivalent, not a tested dose | Dose of the rat dopamine and serotonin studies.(14) |
| 600 mg/kg, single dose, equal to 97.3 mg/kg human equivalent, about 6.8 g for 70 kg | Rat, route not stated | Animal dose, estimated equivalent, not a tested dose | Suppressed behavioral activity.(13) |
Estimated equivalent, not a tested dose: the human-equivalent dose (HED, mg/kg) equals the animal dose (mg/kg) x (animal Km / human Km), with Km 6 for rats and 37 for humans and a 70 kg adult. For 30 mg/kg that is 30 x 6/37 = 4.86 mg/kg. The 30 and 50 mg/kg equivalents are 2.3 and 3.8 times the 150 mg per day upper trial dose (the ratio is to the trial dose, not to the label’s 200 mg per day maximum); they show where the animal effects sit and are not a dose to use.
Community anecdotal range (not a trial dose): users commonly report taking 50 to 100 mg per day, often 50 mg, and some report up to 150 mg per day. These figures come from user reports, not from a study, and reports differ. The 150 mg per day figure lies inside the label’s daily range of 100 to 200 mg and at the top of the 100 to 150 mg per day used in the placebo-controlled study; the trial doses, the label regimen and the rat-to-human estimates above are separate from this range.
The label advises against taking it after 4 p.m., and no taper schedule is described in the trials listed above. The pharmacokinetic figures above are for oral dosing; no published pharmacokinetic data for sublingual, powder or spray forms were found.
Mechanism of Action
In rats and rat brain tissue, bromantane increased dopamine release and synthesis and inhibited dopamine transport, without acting directly on dopamine D1, D2 or D3 receptors. In a rat study with a single 50 mg/kg intraperitoneal dose (injected into the abdominal cavity), dopamine biosynthesis and release in striatum were stimulated when measured ex vivo (in tissue taken after dosing), with no change in serotonin formation in striatum or frontal cortex.(15) In the same paper, bromantane inhibited the active transport of dopamine in rat striatal synaptosomes (isolated nerve-ending preparations) at an IC50 of 3.56 microM, the concentration that blocks half of the transport, and it had no direct effect on dopamine D1, D2 or D3 receptors in rat striatum in vitro.(15)
In rats given a high 100 mg/kg dose, dopamine release from the striatum peaked 2 hours after ingestion at 5 times the control (untreated) level, with a second increase at 7 hours at 2.5 to 3.5 times the normal level.(4) The same letter reports that bromantane’s stimulatory effect on motor activity in rats occurs in two phases, a peak 2 hours after ingestion and a second peak 6 to 7 hours after ingestion, which fits this time course.(4)
An increase in dopamine synthesis and release would, if it occurs at human doses, fit the lower fatigue seen in the asthenia trials; this is inferred, not measured in humans.
The Russian prescribing information attributes the action to stronger dopamine release from nerve terminals, blockade of its reuptake and increased biosynthesis,(12) and it also describes modulation of the GABA-benzodiazepine receptor complex and stronger GABA signalling.(12) Whether dopamine-transporter inhibition matters at human doses is unsettled: the in vitro IC50 is micromolar, while the label names reuptake blockade.
In anesthetized rats, bromantane increased stroke and minute blood volume at a reduced heart rate and peripheral resistance, while arterial pressure showed an insignificant short-time increase.(16) Human cardiovascular data are limited: one probably related blood-pressure rise in the 795-patient study(6) and, in the 40-patient Avedisova study, laboratory tests and ECG that showed no negative effect on the patients’ physical state.(9)
The exact mechanism of action in humans is still unknown.
How Bromantane Differs from Amphetamine and Modafinil
Bromantane is described as raising dopamine mainly by increasing its synthesis and release, with transporter inhibition seen only at micromolar concentrations in vitro, whereas amphetamine acts directly on the dopamine transporter and modafinil inhibits it with low affinity. The amphetamine and modafinil descriptions are general pharmacology; the bromantane description is inferred from rat and in vitro data.
In a comparison with Adderall (amphetamine salts), modafinil and noopept, bromantane is commonly described by users as a milder, calmer stimulant with less of a rush than amphetamine, with a stimulant-plus-anxiolytic profile that modafinil and noopept are not described as having; reports differ, and the human trials listed above do not compare bromantane with any of the three, so these differences are inferred from mechanism and user reports rather than tested.
Modulation of Neurotransmitters
In rats given 50 mg/kg orally, bromantane raised 5-HT (serotonin) and 5-HIAA (its breakdown product) content in the frontal cortex, produced a delayed increase in subcortical regions and left a stable decrease in the cerebellum, and it also changed dopamine parameters.(14) The intraperitoneal rat study above found no change in serotonin formation, and the two results differ by route and measure, so the serotonin effect is not settled.
Gene Expression Changes
A single 50 mg/kg oral dose differentially regulated tyrosine hydroxylase (the enzyme that makes the dopamine precursor L-DOPA) mRNA (the gene’s messenger copy) and protein, and dopamine and L-DOPA content, across several rat brain regions.(17) In rats given 50 mg/kg, accumulation of L-DOPA and dopamine correlated with transcription of the tyrosine hydroxylase and DOPA-decarboxylase genes, and the authors conclude that ladasten activates de novo synthesis of both enzymes.(18) A single 50 mg/kg dose is also reported to activate gene expression for the neurotrophins BDNF and NGF (nerve growth-support proteins) and for mitogen-activated kinases (cell-signaling enzymes) in rat brain.(19) Whether these changes occur in the human brain has not been shown.
Bromantane Pharmacokinetics: Onset, Peak and Half-Life
The Russian prescribing information for Ladasten gives a human elimination half-life of 11.21 hours and a peak blood concentration at 2 to 4 hours.(12) Oral bromantane has 42% bioavailability and peaks at 2.75 hours in women and 4.0 hours in men;(1) in rats the half-life is 7 hours (animal data).(4)
In rats the plasma maximum came 1 hour after dosing, when the brain concentration was four times the blood concentration.(4)
Bromantane is highly lipophilic, is distributed into brain and fat tissue and is finally deposited in adipose tissue.(1) Metabolism is mainly hydroxylation at the 6th position of the adamantane ring, and metabolites remain detectable in urine for two weeks after administration.(1) In the multicenter patient study the antiasthenic effect was seen on day 3 and persisted for one month after withdrawal.(6)
The label does not state a duration of action per dose and gives two doses per day;(12) that schedule fits the 11.21-hour half-life (inferred), and users commonly report effects lasting roughly 8 to 12 hours after an oral dose, though reports differ.
Nootropic Benefits of Bromantane
Bromantane is discussed as a nootropic, but it is a stimulant-anxiolytic whose human measurements are of asthenia, fatigue and psychophysiological indices such as attention and operator performance; no memory test in healthy adults is reported.
1. Asthenia and Fatigue
In a randomized blind 28-day study, ladasten was superior to placebo in the rate and degree of reduction of main asthenic symptoms in neurasthenia.(10) Asthenia was the condition studied in the human trials; the figures are in the evidence table above.
2. Cognitive Function and Mental Fatigue
In healthy volunteers, the effects of a single 100 mg dose of ladasten were more pronounced in stress-labile individuals.(11) In the 10-volunteer EEG study, the oral dose raised middle-frequency alpha-rhythm power and lowered delta and beta1 power.(3) Range and stability of attention, sensorimotor reaction and operator performance are also reported to improve.(1)
A memory benefit in healthy adults has not been shown.
3. Anxiety and Mood
In the multicenter patient study, the authors report clinical efficacy for anxiety-depressive spectrum disorders, autonomic dystonia and sleep disorders.(6)
In a mouse model of anxious depression, ladasten 30 mg/kg intraperitoneally lowered the inflammatory signaling proteins (cytokines) IL-6, IL-17 and IL-4 more strongly than the antidepressant imipramine at 10 mg/kg, removed behavioral changes and restored immune organ indexes (animal data).(20)
4. Physical Performance
Bromantane is reported to increase physical and intellectual working capacity and to inhibit the development of fatigue.(1) Increased resistance to overheating and restoration of working capacity after physical loads are also reported.(1) In rats given 30, 150 or 600 mg/kg orally for two months, the course increased muscle strength (animal data).(21)
5. Learning and Memory
In rat hippocampal slices, 10 microM ladasten transformed short-term potentiation of synaptic transmission (a brief strengthening of nerve connections) into a long-lasting form (in vitro).(17) A dopamine-dependent effect on memory formation would fit this, if it occurs in humans; no human memory test with bromantane has been reported.
6. Sexual Behavior and Libido
In rats, a three-day course of 30 and 300 mg/kg orally mainly increased sexual proceptivity, and a chronic course produced a dose-dependent increase in both proceptivity and receptivity; the authors link this to the dopamine-positive action of bromantane.(22) A male rat study reports activation of spermatogenesis,(23) while a two-month rat study at 30 mg/kg found a non-significant (“unreliable”) decrease in the absolute amount of sperm.(24) These are results in rats.
7. ADHD and Neuroprotection
Bromantane trials enrolled patients with asthenic disorders or neurasthenia, not people with ADHD, so a benefit in ADHD is untested. Memantine, another adamantane derivative, is described as potentially neuroprotective; no neuroprotection outcome with bromantane has been shown in humans.(17)
What Users Report: Community Reports, Not Trial Findings
Community reports, not trial findings: users commonly describe bromantane as giving calmer focus with mild stimulation rather than a pronounced rush, with timing that differs from hours to several days, a few noticing nothing, and trouble sleeping when a dose is taken late. These accounts are general user reports and are not verified.
Bromantane Side Effects & Safety
In the multicenter patient study, adverse events occurred in 23 patients (3%); the dose was lowered in 4 (0.5%) and the drug was stopped in 6 (0.8%).(6) No serious adverse effects were found.(6) The most frequent were drowsiness (7 patients), headache (5) and trouble falling asleep (4); one patient’s blood pressure rose, judged probably related, and the drug was stopped.(6) In the 180-patient placebo-controlled study, 16 ladasten patients had mild adverse events that the authors say did not require withdrawal.(8) Side effects at therapeutic doses, including withdrawal syndrome and hyperstimulation, are described as almost absent.(1)
The Russian label lists over-activation and trouble falling asleep as central nervous system effects, and allergic reactions in people with individual sensitivity.(12) It notes that sedation is possible after a significant overdose(12) and advises a lower dose when central nervous system effects occur.(12)
Commonly reported side effects at typical doses are headache, irritability or restlessness, insomnia if taken late in the day, nausea, dizziness, and fatigue or sedation in some users, with jitteriness at high doses; reports differ between users, and these are user reports and expectations from a stimulant-like profile rather than trial rates. The cited trial adverse-event rates above are the measured figures.
Interactions and Cautions
No human interaction studies of bromantane exist, so the cautions below are inferred from its dopaminergic, stimulant-like profile and from the label. Avoid combining bromantane with MAOIs (monoamine oxidase inhibitors, a class of antidepressants) and ask a pharmacist or doctor first; use caution with SSRIs, SNRIs and other antidepressants, because combining dopamine-active or stimulant-like compounds with serotonergic or monoamine-oxidase-inhibiting drugs may add to their effects and the combination has not been studied.
Avoid combining bromantane with amphetamine, methylphenidate or other strong stimulants, because the combined effect may be stronger than expected (community interaction references advise avoiding this); keep caffeine, if used, to moderate amounts. Ask a pharmacist or doctor before combining it with sedatives or alcohol (beyond the label’s thiopental and benzodiazepine notes below), anticoagulants, thyroid or diabetes medicines, none of which have otherwise been studied with it, and in severe liver or kidney disease. People with hypertension or heart rhythm problems should be cautious because stimulant-like compounds can raise heart rate and blood pressure; this is inferred, and human cardiovascular data are limited to one reported blood-pressure rise and ECG checks in a small study. People with bipolar disorder, mania or psychosis should avoid it, because dopamine-increasing compounds can worsen these conditions.
The Russian label lists pregnancy, breastfeeding, age under 18 and hypersensitivity to its components as contraindications.(12) Human pregnancy and breastfeeding data are lacking. The label’s daily maximum is 200 mg and the highest dose used in the trials above is 150 mg per day; neither figure is advice to take that amount.(12)
Bromantane is reported to stimulate synthesis of cytochrome P-450 (a family of liver enzymes that break down drugs) and reduces the hypnotic action of thiopental sodium;(1) the label gives the thiopental effect and adds that it does not weaken the anxiolytic effect of benzodiazepines.(12)
Stacking (inferred, not tested in trials): none of the human trials listed here tested bromantane in combination with other nootropics, and users commonly pair a stimulant-like compound with L-theanine and, at most, moderate caffeine to soften jitteriness, with a choline source, with racetams, or with adaptogens such as rhodiola (a plant extract used for fatigue). These pairings are inferred from the mechanisms involved and from user practice, and none has been tested with bromantane; adding a second active compound also adds its own side effects, so changes are made one at a time at low doses.
Dependence and Tolerance
No dependence signal was seen in the trials listed above. In the 180-patient placebo-controlled study, no signs of withdrawal syndrome appeared after stopping ladasten, though some patients had mild irritability, anxiety, tiredness, dizziness, headache or sleep problems, which the investigators attributed to residual asthenia.(8) Neznamov’s placebo study, after 28 days of treatment and one week of placebo, reports no withdrawal syndrome, which its authors read as a lack of addictive potential.(10) The Russian label states that Ladasten has no addictive potential.(12) In rats, a two-month course showed no significant behavioral symptoms of dependence(21) and did not produce tolerance to the effect on physical and operant capacity (animal data).(21) Reports on tolerance differ, with effects fading on daily use in some accounts and not in others; no human tolerance data exist.
Animal toxicity: in rats, single doses of 30 to 300 mg/kg stimulated and 600 to 9,600 mg/kg suppressed behavioral activity, mydriasis (pupil dilation) occurred at all doses studied, and rectal temperature fell by 0.5 to 1 degree C after virtually all doses.(13)
Bromantane Legal Status and Anti-Doping
Bromantane is listed as Bromantan among the stimulants prohibited in competition on the WADA 2026 Prohibited List.(25) Anti-doping prohibition of bromantane dates to 1997.(1)
As of a 2012 review, Ladasten is certified in Russia as a drug,(1) and the current Russian prescribing information lists it as a prescription-only medicine; the registration certificate shown there is dated 16 May 2024, while Vidal’s description of the label was last updated on 6 Dec. 2023.(12) In the US, bromantane is not an FDA-approved drug as far as public drug listings show, and no dietary-supplement listing was found, so it does not appear to be a recognised dietary supplement ingredient there; its regulatory status varies by country.
Is Bromantane Legal in the UK?
Bromantane (Ladasten) is not named in UK law, and its status turns on the Psychoactive Substances Act 2016: if it counts as a psychoactive substance, supplying it, importing it and possessing it with intent to supply are offences, while possession for personal use is an offence only in custodial institutions. The Act defines a psychoactive substance as any substance capable of producing a psychoactive effect in a person who consumes it and not exempted,(26) meaning it affects mental functioning or emotional state by stimulating or depressing the central nervous system.(26) Bromantane is a stimulant, so it would probably meet that definition; this is inferred from its action, not a regulator or court finding.
Supplying such a substance is an offence where the supplier knows, or is reckless as to whether (careless about whether), it is likely to be consumed for its psychoactive effects (s.5).(27) Possessing it with intent to supply it for consumption is an offence (s.7).(28) Intentionally importing it is an offence, including where the importer intends to consume it (s.8).(29) Possession for personal use is an offence only in a custodial institution (s.9).(30)(31)
Exempted substances include medicinal products, controlled drugs, caffeine, nicotine and food.(32)
Where to Buy Bromantane
SwissChems lists Bromantane (Ladasten) as a research chemical: 25 mg capsules in a 60-capsule bottle at a current price of $49.99 (USD), labelled for laboratory research use only.(33) Ladasten is the Russian commercial name of bromantane, so a search to buy Ladasten leads to the same compound. Bromantane is sold online mainly by specialist research-chemical vendors, as a capsule or powder, such as the one above. Bromantane is not sold on mainstream marketplaces such as Amazon as far as public listings show, and marketplace policies change. UK supply and import rules are in the legal section above.
Vendor options for other compounds are on the buy nootropics page.
Summary
Bromantane (Ladasten) has human evidence in asthenic disorders from a 180-patient placebo-controlled multicenter study in neurasthenia and somatogenic asthenia (with single-centre reports that probably overlap it) and from a larger patient study without a reported control group; evidence in healthy adults comes from two studies, one with 10 volunteers and one that does not state its size. In rats, bromantane increases dopamine release and synthesis, and an effect on fatigue and motivation in humans is inferred from that.
Its UK status depends on the Psychoactive Substances Act definition, and long-term safety has not been studied.
FAQs
How long does Bromantane take to work?
In the multicenter patient study, bromantane’s antiasthenic effect was seen on day 3 of a 28-day course. After an oral dose, the Russian label gives a blood peak at 2 to 4 hours. A single-dose onset time for cognitive effects in healthy adults has not been measured.
Should you cycle Bromantane?
Cycling schedules for bromantane are not described in the 28-day multicenter patient study or in the 180-patient placebo-controlled study, which gave ladasten or placebo for 28 days followed by 7 days of placebo; the Russian label gives a course of 2 to 4 weeks. In rats, a two-month course did not produce tolerance to its effect on physical and operant capacity.
Can I stack Bromantane with other nootropics?
Bromantane has not been tested with other nootropics in humans; the pairings users report and the cautions that apply are in the Interactions and Cautions section above, where they are labelled as inferred.
- Oliynyk, Sergiy, and Seikwan Oh. “The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance.” Biomolecules & Therapeutics vol. 20,5 446-56. Sept. 2012, doi:10.4062/biomolther.2012.20.5.446↩↩↩↩↩↩↩↩↩↩↩↩↩
- Siuniakov, S A, et al. “[Pilot clinical trial of ladasten].” Eksperimental’naia i klinicheskaia farmakologiia vol. 69,4 10-5. July-Aug. 2006, PMID: 16995430↩↩↩
- Viatleva, O A, et al. “[The neuro- and psychophysiological effects of bromantane].” Voenno-meditsinskii zhurnal vol. 321,8 61-5. Aug. 2000, PMID: 10998997↩↩↩↩
- Burnat, Pascal, et al. “Bromontan, a new doping agent.” The Lancet vol. 350,9082 963-4. 27 Sept. 1997, doi:10.1016/S0140-6736(05)63310-7↩↩↩↩↩
- Smulevich, A B, et al. “[A new approach to the therapy of neurasthenia and somatogenic asthenia: results of a multicenter study of the efficacy and safety of ladasten].” Psikhiatriia i psikhofarmakoterapiia im. P.B. Gannushkina vol. 11,1. 2009↩↩
- Voznesenskaia, T G, et al. “[Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol. 110,5 Pt 1 17-26. 2010, PMID: 21322821↩↩↩↩↩↩↩↩↩↩↩↩↩
- National Center for Biotechnology Information. “Bromantan | C16H20BrN | CID 4660557.” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bromantane↩
- Smulevich, A B, et al. “[A new approach to the therapy of neurasthenia and somatogenic asthenia: results of a multicenter study of the efficacy and safety of ladasten].” Psikhiatriia i psikhofarmakoterapiia im. P.B. Gannushkina vol. 11,1. 2009↩↩↩↩↩↩
- Avedisova, A S, et al. “[Safety and therapeutic efficacy of ladasten in patients with neurasthenia and somatogenic asthenia].” Psikhicheskie rasstroistva v obshchei meditsine no. 1. 2009↩↩
- Neznamov, G G, et al. “[Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol. 109,5 20-6. 2009, PMID: 19491814↩↩↩
- Bogdan, N G, et al. “[Effect of ladasten on the psychophysiological parameters of healthy volunteers].” Eksperimental’naia i klinicheskaia farmakologiia vol. 72,3 3-9. May-June 2009, PMID: 19642584↩↩↩↩
- Ladasten Prescribing Information. Vidal, Russian drug reference based on the manufacturer’s instruction, updated 6 Dec. 2023, https://www.vidal.ru/drugs/ladasten__20677↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
- Iezhitsa, I N, et al. “Toxic Effect of Single Treatment with Bromantane on Neurological Status of Experimental Animals.” Bulletin of Experimental Biology and Medicine vol. 133,4 380-3. Apr. 2002, doi:10.1023/A:1016206306875↩↩↩
- Kudrin, V S, et al. “[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain].” Eksperimental’naia i klinicheskaia farmakologiia vol. 58,4 8-11. July-Aug. 1995, PMID: 7580761↩↩
- Zimin, I A, et al. “[Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb].” Eksperimental’naia i klinicheskaia farmakologiia vol. 73,2 2-5. Feb. 2010, PMID: 20369592↩↩
- Morozov, I S, et al. “[The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals].” Eksperimental’naia i klinicheskaia farmakologiia vol. 63,1 33-6. Jan.-Feb. 2000, PMID: 10763107↩
- Mikhaylova, M, et al. “The Effects of Ladasten on Dopaminergic Neurotransmission and Hippocampal Synaptic Plasticity in Rats.” Neuropharmacology. Oct. 2007, PMID: 17854844↩↩↩
- Vakhitova, Iu V, et al. “[Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain].” Eksperimental’naia i klinicheskaia farmakologiia vol. 67,4 7-11. July-Aug. 2004, PMID: 15500036↩
- Salimgareeva, M Kh, et al. “Mechanisms of Action of Ladasten: Activation of Gene Expression for Neurotrophins and Mitogen-Activated Kinases.” Bulletin of Experimental Biology and Medicine vol. 152,3 313-7. Jan. 2012, doi:10.1007/s10517-012-1516-z↩
- Tallerova, A V, et al. “[Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice].” Eksperimental’naia i klinicheskaia farmakologiia vol. 74,11 3-5. 2011, PMID: 22288152↩
- Iezhitsa, I N, et al. “[Effect of bromantane on the rat neurologic status in two month course].” Eksperimental’naia i klinicheskaia farmakologiia. Sept. 2000, PMID: 11109517↩↩↩
- Kuzubova, E A, et al. “[The effect of bromantan on the sexual behavior and conception in rats].” Eksperimental’naia i klinicheskaia farmakologiia vol. 67,3 34-7. May-June 2004, PMID: 15341065↩
- Khamidova, T V, et al. “[Effect of ladasten on reproduction function in male rats].” Eksperimental’naia i klinicheskaia farmakologiia vol. 68,3 26-9. May-June 2005, PMID: 16047676↩
- Khamidova, T V, et al. “[Effect of the long term administration of bromantan on the reproductive function in rats].” Eksperimental’naia i klinicheskaia farmakologiia vol. 63,3 36-9. May-June 2000, PMID: 10934594↩
- World Anti-Doping Agency. “World Anti-Doping Code International Standard: Prohibited List 2026.” WADA, Sept. 2025, https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf↩
- UK Parliament. “Psychoactive Substances Act 2016, section 2.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/2↩↩
- UK Parliament. “Psychoactive Substances Act 2016, section 5.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/5↩
- UK Parliament. “Psychoactive Substances Act 2016, section 7.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/7↩
- UK Parliament. “Psychoactive Substances Act 2016, section 8.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/8↩
- UK Parliament. “Psychoactive Substances Act 2016, section 9.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/9↩
- Home Office. “Psychoactive Substances Act 2016: Explanatory Notes.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/notes/contents↩
- UK Parliament. “Psychoactive Substances Act 2016, Schedule 1.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/schedule/1↩
- SwissChems. “Bromantane (25mg/capsule), 60 Capsules.” SwissChems, https://swisschems.is/product/bromantane-25mg-capsule-60-capsules/↩

